Information Provided By: 
Fly News Breaks for April 27, 2016
IRWD
Apr 27, 2016 | 08:57 EDT
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.
News For IRWD From the Last 2 Days
There are no results for your query IRWD
